Author

F. Levi-Schaffer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:mechanistic / dynamical model· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Jarjoui· 1 shared A. Tzankov· 1 shared B. Tirosh· 1 shared C. Martin· 1 shared C. Zinner· 1 shared D. Reichmann· 1 shared E. Ben-Chetrit· 1 shared E. Orenbuch-Harroch· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Jarjoui

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

KIRA6 is an effective and versatile mast cell inhibitor of IgE-mediated activation

T. Wilhelm, V. Wunderle, S. Boukeileh, J. Gossen, M. A. Margreiter, R. Sakurov, S. Capellmann, M. Schwoerer, N. Ahmed, G. Bronneberg, M. Arock, C. Martin, T. Schubert, F. Levi-Schaffer, G. Rossetti, , M. Huber

This study identifies KIRA6 as a dual inhibitor of LYN and FYN that suppresses IgE-mediated mast cell activation and inflammation.

bioRxiv · Apr 18, 2024Immunology

COVID-19 patients have increased levels of membrane-associated and soluble CD48

H. Pahima, I. Zaffran, E. Ben-Chetrit, A. Jarjoui, P. Gaur, M. L. Manca, D. Reichmann, E. Orenbuch-Harroch, I. Puxeddu, C. Zinner, A. Tzankov, F. Levi-Schaffer

The paper finds increased levels of membrane-bound and soluble CD48 in COVID-19 patients through various assays, suggesting a potential therapeutic target.

bioRxiv · Mar 18, 2022 · PreprintImmunology